These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 16240976)

  • 1. Acute cholestatic hepatitis probably associated with risperidone.
    Llinares Tello F; Hernández Prats C; Bosacoma Ros N; Pérez Martínez E; Climent Grana E; Navarro Polo JN; Ordovás Baines JP
    Int J Psychiatry Med; 2005; 35(2):199-205. PubMed ID: 16240976
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Risperidone-induced cholestatic hepatitis.
    Krebs S; Dormann H; Muth-Selbach U; Hahn EG; Brune K; Schneider HT
    Eur J Gastroenterol Hepatol; 2001 Jan; 13(1):67-9. PubMed ID: 11204814
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Hepatic tolerance of atypical antipsychotic drugs].
    Dumortier G; Cabaret W; Stamatiadis L; Saba G; Benadhira R; Rocamora JF; Aubriot-Delmas B; Glikman J; Januel D
    Encephale; 2002; 28(6 Pt 1):542-51. PubMed ID: 12506267
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Liver enzyme abnormalities during antipsychotic treatment: a case report of risperidone-associated hepatotoxicity.
    López-Torres E; Süveges A; Peñas-LLedó EM; Doña A; Dorado P; LLerena A; Berecz R
    Drug Metabol Drug Interact; 2014; 29(2):123-6. PubMed ID: 24598833
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Disorder of liver functions in a schizophrenic patient after long-term risperidone treatment--case report].
    Radzik J; Grotthus B; Leszek J
    Psychiatr Pol; 2005; 39(2):309-13. PubMed ID: 15881625
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Case study: risperidone-induced hepatotoxicity in pediatric patients.
    Kumra S; Herion D; Jacobsen LK; Briguglia C; Grothe D
    J Am Acad Child Adolesc Psychiatry; 1997 May; 36(5):701-5. PubMed ID: 9136506
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Risperidone-induced hepatotoxicity.
    Benazzi F
    Pharmacopsychiatry; 1998 Nov; 31(6):241. PubMed ID: 9930641
    [No Abstract]   [Full Text] [Related]  

  • 8. Rapid onset of risperidone-induced hepatotoxicity.
    Phillips EJ; Liu BA; Knowles SR
    Ann Pharmacother; 1998; 32(7-8):843. PubMed ID: 9681106
    [No Abstract]   [Full Text] [Related]  

  • 9. Risperidone-induced hepatotoxicity?
    Geller WK; Zuiderwijk PB
    J Am Acad Child Adolesc Psychiatry; 1998 Mar; 37(3):246-7. PubMed ID: 9519624
    [No Abstract]   [Full Text] [Related]  

  • 10. Risperidone- and quetiapine-induced cholestasis.
    Wright TM; Vandenberg AM
    Ann Pharmacother; 2007 Sep; 41(9):1518-23. PubMed ID: 17666578
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Risperidone-induced hepatotoxicity in a patient addicted to synthetic cannabinoid.
    Saglam O; Bahsi R; Akkoca Y; Filik L
    Eur J Gastroenterol Hepatol; 2016 Mar; 28(3):360-1. PubMed ID: 26825144
    [No Abstract]   [Full Text] [Related]  

  • 12. Risperidone rechallenge for marked liver function test abnormalities in an autistic child.
    Copur M; Erdogan A
    Recent Pat Endocr Metab Immune Drug Discov; 2011 Sep; 5(3):237-9. PubMed ID: 21913889
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pancreatitis and cholestatic hepatitis induced by risperidone.
    Cordeiro Q; Elkis H
    J Clin Psychopharmacol; 2001 Oct; 21(5):529-30. PubMed ID: 11593080
    [No Abstract]   [Full Text] [Related]  

  • 14. Remission of drug-induced hepatitis after switching from risperidone to paliperidone.
    Paulzen M; Orfanos S; Gründer G
    Am J Psychiatry; 2010 Mar; 167(3):351-2. PubMed ID: 20194492
    [No Abstract]   [Full Text] [Related]  

  • 15. Chronically administered risperidone did not change the number of hepatocytes in rats: a stereological and histopathological study.
    Halici Z; Keles ON; Unal D; Albayrak M; Suleyman H; Cadirci E; Unal B; Kaplan S
    Basic Clin Pharmacol Toxicol; 2008 May; 102(5):426-32. PubMed ID: 18248514
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neuroleptic malignant syndrome during a change from haloperidol to risperidone.
    Reeves RR; Mack JE; Torres RA
    Ann Pharmacother; 2001 Jun; 35(6):698-701. PubMed ID: 11408988
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Is liver function monitoring warranted during risperidone treatment?
    Landau J; Martin A
    J Am Acad Child Adolesc Psychiatry; 1998 Oct; 37(10):1007-8. PubMed ID: 9785708
    [No Abstract]   [Full Text] [Related]  

  • 18. Management of marked liver enzyme increase during olanzapine treatment: a case report and review of the literature.
    Manceaux P; Constant E; Zdanowicz N; Jacques D; Reynaert C
    Psychiatr Danub; 2011 Sep; 23 Suppl 1():S15-7. PubMed ID: 21894094
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Urinary retention caused after fluoxetine-risperidone combination.
    Bozikas V; Petrikis P; Karavatos A
    J Psychopharmacol; 2001 Jun; 15(2):142-3. PubMed ID: 11448089
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Risperidone-associated hepatotoxicity.
    Fuller MA; Simon MR; Freedman L
    J Clin Psychopharmacol; 1996 Feb; 16(1):84-5. PubMed ID: 8834428
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.